REG - e-Therapeutics plc - Filing of eight patent applications

E-TherapeuticsAnnouncement

01/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220801:nRSA3245Ua&default-theme=true

RNS Number : 3245U  e-Therapeutics plc  01 August 2022

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Filing of eight patent applications on

proprietary GalNAc-siRNA technology and target related innovation

 

 

London, UK, 1 August 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
specialist in computational drug discovery with a focus on developing RNA
interference ("RNAi") therapeutics, today announced the filing of eight
further patent applications in the United States ("US") to protect innovation
arising from e-therapeutics' proprietary GalNAc-siRNA technology.

 

The Company uses its proprietary GalNAc-siRNA technology to silence any gene
in liver hepatocytes.  As announced on 26 October 2021,
e-therapeutics' GalNAc-siRNA constructs have demonstrated compelling in
vivo performance in terms of depth of gene silencing and duration of action.

 

The eight patent applications relate to innovation arising from the Company's
work on its pipeline of pre-clinical siRNA candidates in several therapeutic
areas and include innovation around novel target ideas and associated
disease-relevant biology identified using the Company's computational
platform, novel siRNA therapeutics and novel siRNA chemistries associated with
such siRNA therapeutics.

 

This news follows e-therapeutics' announcement on 4 May 2022, as part of its
year-end results statement, that eleven patent applications had been filed to
protect proprietary and novel GalNAc-siRNA silencing construct designs.

 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

"This second announcement of significant patent filings within three months
demonstrates fast and meaningful scientific and technological progress. It
also reflects our commitment to protecting the Company's proprietary
innovation, which forms a critical part of our strategy as we continue to make
material steps in developing a computationally driven in-house pipeline of
highly differentiated RNAi medicines at speed. Our computational platform not
only affords us an important advantage in drug discovery, but also in IP
strategy, and we are leveraging this position in our patent
applications."

 

 

 

Enquiries:

 e-therapeutics plc
 Ali Mortazavi,                                                                        Tel: +44 (0)20 4551 8888
 CEO

                                                                                     www.etherapeutics.co.uk
 James Chandler, VP IR & Communications

      SP Angel Corporate Finance LLP

                                                                                       Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 
About e-therapeutics plc

 

e-therapeutics plc is a UK-based company integrating computational power and
biological insight to accelerate the discovery of life-transforming medicines.
The Company has developed and validated a powerful, disease- and
modality-agnostic computational approach to drug discovery, leveraging its
industry-leading expertise in network biology to capture and interrogate human
disease complexity more fully.

 

The Company's multi-disciplinary team builds computational models of
biological functions to transform the search for new medicines, interventions,
mechanisms and genetic support. Its biology-led in silico laboratory enables
rapid hypothesis generation and screening. Novel targets can also be
identified, prioritised and assessed. Harnessing internal target gene
discoveries, e- therapeutics is currently building an in-house pipeline of
RNAi based medicines, using its proprietary GalNAc-siRNA technology.

 

e-therapeutics has deployed and validated its computational drug discovery
platform both in house and with partners, including Novo Nordisk, Galapagos
NV, iTeos and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFVEDIIAFIF